Skip to main content

Table 3 Generalizability of the individual trials to the hypertensive population.

From: Generalizability of guidelines and physicians' adherence. Case study on the Sixth Joint National Commitee's guidelines on hypertension

  % of the pop. eligible* for trial % of the eligible pop. that would be excluded** % of the pop. to which the trial is generalizable
VA-NHBLI [36] 9.7 14.1 8.3
HDPF [37] 28.8 0 28.8
Oslo [45] 3.3 10.6 2.9
Australia [43] 18.1 5.7 17.1
MRC [40] 21.0 0 21.0
VA I [34] 0.4 0 0.4
VA II [35] 18.9 0 18.9
PHS [44] 18.5 9 16.9
HSCSG [33] 1.2 1.1 1.2
Barraclough [32] 11.0 0 11.0
Carter [38] 2.6 25 1.8
EWPHE [39] 37.4 22.3 32.8
Coope [42] 14.2 22.1 11.1
MRC – O [29] 14.8 9.7 13.2
SHEP [41] 22.0 26.5 16.2
STOP [30] 2.1 3.2 2.1
  1. * Eligibility criteria shown in table 2. People with hypertension and controlled blood pressure was excluded from the analysis. ** Exclusion criteria shown in table 2.